This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-03. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Among those from the world of politics to be recognised in the 2024 Birthday Honours is former prime minister Gordon Brown, who is made a Companion of Honour, and former MP Wayne David, who receives a knighthood. 16 June – Grant StClair-Armstrong, the Reform UK candidate for North West Essex, resigns from the party after historic blog posts emerge in which he urged people to vote for the British National Party. ITV Wales holds an election debate between senior figures from the three main political parties in Wales; David TC Davies (Conservative), Jo Stevens (Labour) and Liz Saville Roberts (Plaid Cymru). 17 June – Nigel Farage launches Reform UK's election manifesto, which he describes as a contract, and which chiefly proposes a freeze on non-essential immigration. Lord Cashman is suspended from the Parliamentary Labour Party for describing Rosie Duffield as "frit or lazy" in a social media post for withdrawing from hustings meetings over concerns for her safety. BBC Sounds launches an Election 2024 livestream, bringing together all the election news and programming, such as Newscast, Today, Question Time and Sunday with Laura Kuenssberg. The livestream is scheduled to run until 8 July. 18 June – LBC's Nick Ferrari presents the first of two editions of Britain's Next PM, a phone-in giving listeners the opportunity to speak to Keir Starmer and Rishi Sunak, with Starmer appearing on the first edition and Sunak the following day. The deadline for people wishing to register to vote in time for the 2024 general election expires at 23:59.
Plutonium is a reactive metal. In moist air or moist argon, the metal oxidizes rapidly, producing a mixture of oxides and hydrides. If the metal is exposed long enough to a limited amount of water vapor, a powdery surface coating of PuO2 is formed. Also formed is plutonium hydride but an excess of water vapor forms only PuO2. Plutonium shows enormous, and reversible, reaction rates with pure hydrogen, forming plutonium hydride. It also reacts readily with oxygen, forming PuO and PuO2 as well as intermediate oxides; plutonium oxide fills 40% more volume than plutonium metal. The metal reacts with the halogens, giving rise to compounds with the general formula PuX3 where X can be F, Cl, Br or I and PuF4 is also seen. The following oxyhalides are observed: PuOCl, PuOBr and PuOI. It will react with carbon to form PuC, nitrogen to form PuN and silicon to form PuSi2. The organometallic chemistry of plutonium complexes is typical for organoactinide species; a characteristic example of an organoplutonium compound is plutonocene. Computational chemistry methods indicate an enhanced covalent character in the plutonium-ligand bonding. Powders of plutonium, its hydrides and certain oxides like Pu2O3 are pyrophoric, meaning they can ignite spontaneously at ambient temperature and are therefore handled in an inert, dry atmosphere of nitrogen or argon. Bulk plutonium ignites only when heated above 400 °C. Pu2O3 spontaneously heats up and transforms into PuO2, which is stable in dry air, but reacts with water vapor when heated.
The history of biology traces the study of the living world from ancient to modern times. Although the concept of biology as a single coherent field arose in the 19th century, the biological sciences emerged from traditions of medicine and natural history reaching back to Ayurveda, ancient Egyptian medicine and the works of Aristotle, Theophrastus and Galen in the ancient Greco-Roman world. This ancient work was further developed in the Middle Ages by Muslim physicians and scholars such as Avicenna. During the European Renaissance and early modern period, biological thought was revolutionized in Europe by a renewed interest in empiricism and the discovery of many novel organisms. Prominent in this movement were Vesalius and Harvey, who used experimentation and careful observation in physiology, and naturalists such as Linnaeus and Buffon who began to classify the diversity of life and the fossil record, as well as the development and behavior of organisms. Antonie van Leeuwenhoek revealed by means of microscopy the previously unknown world of microorganisms, laying the groundwork for cell theory. The growing importance of natural theology, partly a response to the rise of mechanical philosophy, encouraged the growth of natural history (although it entrenched the argument from design). Over the 18th and 19th centuries, biological sciences such as botany and zoology became increasingly professional scientific disciplines. Lavoisier and other physical scientists began to connect the animate and inanimate worlds through physics and chemistry.
Sources: en.wikipedia.org
=== Pregnancy === It is possible that relaxin in the placenta could be a contributing factor to inducing labour in humans and therefore serum relaxin levels during pregnancy have been linked to premature birth.
In some jurisdictions, designer drugs may fall under analog acts which impose restrictions upon substances which are substantially chemically or pharmacologically similar to existing controlled substances.
The three substrates of this enzyme are saccharopine, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are L-glutamic acid, L-allysine, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is N6-(L-1,3-dicarboxypropyl)-L-lysine:NADP+ oxidoreductase (L-glutamate-forming). Other names in common use include saccharopine (nicotinamide adenine dinucleotide phosphate,, glutamate-forming) dehydrogenase, aminoadipic semialdehyde-glutamic reductase, aminoadipate semialdehyde-glutamate reductase, aminoadipic semialdehyde-glutamate reductase, epsilon-N-(L-glutaryl-2)-L-lysine:NAD+(P) oxidoreductase, (L-2-aminoadipate-semialdehyde forming), saccharopine reductase, 6-N-(L-1,3-dicarboxypropyl)-L-lysine:NADP+ oxidoreductase, and (L-glutamate-forming). This enzyme participates in lysine biosynthesis and lysine degradation.
Sources: en.wikipedia.org
In August, while appearing on an episode Alex Cooper's podcast Call Her Daddy, Hunter Schafer said, "The real tea is I have no fucking idea what's going on" with production on the series' third season. Zendaya said she did not "really have much of an answer" for the future of Euphoria other than it was set to start filming in January 2025. Colman Domingo said that Levinson had "told me some of it, and it's going to be groundbreaking." Angus Cloud's death from a drug overdose on July 31, 2023, impacted Levinson's teleplays. Speaking to The New York Times, he said "I had a good portion of it done before the strike [began in May 2023]. Angus was the backbone of that season. I used to even talk to him about it because I wanted him to stay clean. So I would invite him over and I'd tell him what the plans were for the character. I'd say, look, he's been in prison for a few years, so you've got to get that yoked prison body. Because I wanted him to start working out and taking care of himself. You know, season 1 he was supposed to die at the end and I couldn't do it. On May 31, 2026, the same day that the final episode of the third season was released, HBO confirmed that the series had concluded after three seasons. In an interview with The New York Times, Levinson elaborated on his decision to end the series and stated: "In terms of the story that we set out to tell, which is a story about addiction and its consequences, this feels like the end to me".
The main step of the process is the negative selection of newly generated trypsin peptides using a specialized polymer. The polymer ignores the unreactive primary amines blocked by their tags, allowing them to be separated from trypsin generated peptides by ultrafiltration for Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) analysis. These mature and neo-N-termini will differ in ratios between the protease treated versus untreated samples and make up the proteolytic fingerprint of a protease. TAILS is also compatible with Stable isotope labeling by amino acids in cell culture (SILAC). COFRADIC was the earliest technique to capitalize on negative selection to enrich for protein N-termini. Sample proteins are first blocked by reduction and alkylation at their primary amines before endopeptidase treatment. Its negative selection method relies on strong cation exchange chromatography (SCX) to enrich for peptides representing N- and C-termini of proteins based on differences in peptide charge and pH. Additional orthogonal chromatography treatments change the biochemical character of the peptides for further enrichment before final LC-MS/MS analysis. Groups have continued to adapt and improve this technology for protease-substrate discovery. C-terminomics has always been complicated due to the chemical nature of its targets. Carboxyl groups are less reactive than primary amines, making C-terminomic techniques more complex than established N-terminomic approaches.
== Publications == The ISI identified cold fusion as the scientific topic with the largest number of published papers in 1989, of all scientific disciplines. The Nobel Laureate Julian Schwinger declared himself a supporter of cold fusion in the fall of 1989, after much of the response to the initial reports had turned negative. He tried to publish his theoretical paper "Cold Fusion: A Hypothesis" in Physical Review Letters, but the peer reviewers rejected it so harshly that he felt deeply insulted, and he resigned from the American Physical Society (publisher of PRL) in protest. The number of papers sharply declined after 1990 because of two simultaneous phenomena: first, scientists abandoned the field; second, journal editors declined to review new papers. Consequently, cold fusion fell off the ISI charts. Researchers who got negative results turned their backs on the field; those who continued to publish were simply ignored. A 1993 paper in Physics Letters A was the last paper published by Fleischmann, and "one of the last reports [by Fleischmann] to be formally challenged on technical grounds by a cold fusion skeptic." The Journal of Fusion Technology (FT) established a permanent feature in 1990 for cold fusion papers, publishing over a dozen papers per year and giving a mainstream outlet for cold fusion researchers. When editor-in-chief George H. Miley retired in 2001, the journal stopped accepting new cold fusion papers.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.